CDK4/6 inhibition: the late harvest cycle begins

作者
Shom Goel,Jean J. Zhao
出处
期刊:Oncotarget [Impact Journals LLC]
卷期号:7 (31): 48854-48856 被引量:4
标识
DOI:10.18632/oncotarget.9576
摘要

Effective and safe pharmacologic inhibition of the cyclin dependent kinases (CDKs) has been a goal of cancer researchers for many years. CDKs are attractive therapeutic targets in cancer for two main reasons first, some tumors harbor dependencies on particular CDKs for their initiation and maintained growth; second, there is a surprising amount of redundancy between various CDKs in maintaining normal organ function [1, 2]. These observations suggest that it might be possible to inhibit a certain CDK to slow tumor growth without invoking prohibitive toxicity. Unfortunately, clinical trials using CDK inhibitors have largely failed due to low potency and specificity of the agents used. Recently, however, medicinal chemists have developed a new generation of more potent and selective CDK inhibitors. Of these, inhibitors of CDK4 and CDK6 (“CDK4/6 inhibitors”) are the best characterized and have progressed furthest in clinical development. Indeed, recent trials have shown that the addition of palbociclib (a potent and selective CDK4/CDK6 inhibitor) to endocrine therapy significantly improves progression-free survival in women with advanced hormone receptor-positive breast cancer, leading to its accelerated approval by the FDA in 2015 [3]. This success has sparked enthusiasm for CDK4/6 inhibitors and a large number of trials testing CDK4/6 inhibition for a variety of tumor types have opened. Agents in development include palbociclib, abemaciclib, and ribociclib. The canonical function of CDKs 4 and 6 is to facilitate cellular transition from G1 to S phase of the cell cycle. This is achieved when levels of a D-type cyclin (cyclin D1, D2, or D3) rise in G1, facilitating formation of a cyclin D-CDK4/6 holoenzyme (also incorporating a Cip/Kip subunit such as p21 or p27) [4]. The active kinase phosphorylates the retinoblastoma tumor suppressor protein (RB), liberating RB from E2F family transcription factors. This promotes expression of genes regulating the G1-S transition. It is not surprising, therefore, that pharmacologic CDK4/6 inhibitors suppress RB phosphorylation, induce G1 arrest, and ultimately produce a senescent-like phenotype in sensitive tumor cells. Indeed, these effects alone are likely to render these agents as effective therapies for many tumors. Understanding these canonical CDK4/6 pathways might allow us to rapidly identify tumors that are likely to be sensitive to pharmacologic inhibition of these kinases. Potential candidates include: (i) tumors driven by oncogenes that are known to increase cyclin D protein Editorial

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FeiYuan发布了新的文献求助10
1秒前
1秒前
momo完成签到,获得积分10
2秒前
洁净艳一完成签到,获得积分10
2秒前
于念发布了新的文献求助10
3秒前
王贺发布了新的文献求助10
3秒前
慕青的应助被温婉的凌寒采纳,获得10
4秒前
aki完成签到 ,获得积分10
4秒前
852的应助被道之道采纳,获得10
5秒前
闪闪婴发布了新的文献求助30
5秒前
嘿哟yu发布了新的文献求助10
5秒前
玉渊潭完成签到,获得积分10
5秒前
天道酬勤发布了新的文献求助10
5秒前
7秒前
7秒前
7秒前
orixero的应助被han采纳,获得20
7秒前
8秒前
Lucas的应助被tiezhu采纳,获得10
8秒前
kwokai完成签到,获得积分10
8秒前
饼子完成签到 ,获得积分10
8秒前
9秒前
9秒前
9秒前
小蘑菇的应助被shiyi11采纳,获得10
10秒前
汤一德完成签到,获得积分10
10秒前
10秒前
做生活的嚼嚼者完成签到,获得积分10
11秒前
11秒前
啦啦啦发布了新的文献求助10
11秒前
香蕉觅云的应助被阔叶采纳,获得10
12秒前
然12138完成签到,获得积分10
13秒前
赫江涛发布了新的文献求助10
13秒前
14秒前
可爱的函函的应助被罗斯味SF采纳,获得10
14秒前
14秒前
闪闪婴发布了新的文献求助10
14秒前
闪闪婴发布了新的文献求助10
14秒前
闪闪婴发布了新的文献求助10
14秒前
闪闪婴发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578670
关于积分的说明 21861341
捐赠科研通 7791469
什么是DOI,文献DOI怎么找? 3436771
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483557